FDA approves Teva's injectable Treanda

Treanda is for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced that the US Food and Drug Administration (FDA) has approved a new injectable version Treanda for treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and chronic lymphocytic leukemia.

Teva notes that it has not been established whether Treanda is more effective in treating chronic lymphocytic leukemia than other therapies, except for chlorambucil.

Teva gained Treanda through its acquisition of Cephalon in 2011.

The new liquid formulation removes the step of reconstituting lyophilized powder with sterile water prior to adding the medicine to the dilutent and administering to a patient. "By eliminating the need for reconstitution, a step is removed making dose preparation fast and convenient for healthcare professionals,” said Prof. Jim Koeller of the University of Texas at Austin.

"With this new liquid formulation of TREANDA, we are building on the legacy of Treanda, which has played a valuable role since 2008 in the treatment of patients with chronic lymphocytic leukemia or indolent B-cell non-Hodgkin lymphoma that has progressed," said Teva VP and Teva Oncology general manager Bill Campbell.

Published by Globes [online], Israel business news - www.globes-online.com - on September 17, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס